Lenz Therapeutics (NASDAQ:LENZ) Reports Strong Q2 Performance Amid VIZZ Commercial Launch

• Lenz Therapeutics (NASDAQ:LENZ) is actively progressing the commercial launch of VIZZ, its innovative presbyopia treatment, with new marketing strategies and telehealth options driving increased prescriptions.
• Investment firm Piper Sandler adjusted its price target for Lenz Therapeutics to $7.00, indicating a potential upside of 34.4% from its trading price at the time of the update.
• The company delivered robust second-quarter financial results, with total revenues reaching $5.5 million, significantly surpassing analyst estimates by 148.24%, and reporting a narrower-than-expected loss per share of $1.02.

Lenz Therapeutics (NASDAQ:LENZ) is a pharmaceutical company focused on its main product, VIZZ. This is an eye solution used to treat presbyopia, a common age-related eye condition. The company is currently working on the commercial launch of VIZZ and has partnership agreements outside of the United States.

On August 12, 2026, investment firm Piper Sandler lowered its price target on Lenz Therapeutics to $7.00 from a previous target of $12.00. At that time, the stock was trading at $5.21 per share. This new price target suggests a potential increase of about 34.4% from its trading price on that day.

The company recently reported its second-quarter financial results. It announced total revenues of $5.5 million, which was higher than the $5 million reported in the same quarter last year. As highlighted by Zacks, this revenue figure beat analyst estimates by a significant 148.24%, showing stronger than expected performance.

This revenue includes $1.7 million from product sales and $3.8 million from license agreements. The company sold about 27,000 monthly packs of VIZZ, a 9% volume increase from the first quarter. Management noted that new TV advertising and a telehealth option helped increase prescription activity and new patient starts in July.

For the second quarter, Lenz Therapeutics posted a loss of $1.02 per share. This was better than the expected loss of $1.21 per share, marking a positive earnings surprise of 15.70%. The company has a market capitalization of approximately $163.36 million, and its stock has traded between a low of $4.68 and a high of $50.40 over the past 52 weeks.